Physicians' Academy for Cardiovascular Education

Anticoagulation 2017: The key lessons and implications from recent clinical trials (2)

Latest frontiers in anticoagulation therapy (2/4)

15' education - Jan. 12, 2018 - Prof. John Eikelboom, prof. Saskia Middeldorp, Dr. Hanna Pohjantähti-Maaroos

Prof. John Eikelboom summarizes results from COMPASS / Hokusai VTE Cancer trials and discusses the implications for clinical practice


Show transscript

Video navigation menu

  • COMPASS: Rivaroxaban with or without aspirin for CV prevention 00:24
  • Hokusai VTE-Cancer: LMWH/edoxaban versus dalteparin for VTE associated with cancer 03:31
  • Net clinical benefit of COMPASS 05:51
  • In what kind of patients should the combination of rivaroxaban and aspirin be used? 07:12
  • Will the results of the edoxaban cancer study change clinical practice? 10:19
  • Exclusion of G-I cancers in the Hokusai VTE Cancer trial 13:00

Educational information

This educational video is part of a series called Latest frontiers in anticoagulation therapy and recorded during an EBAC accredited session held on January 12, 2018

Educational objective:

To overall objective is to provide an expert perspective on the appropriate use of NOACs in clinical practice

Educational objectives of the CME session were to:

This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.



Prof. John Eikelboom, Associate Professor in the Department of Medicine at McMaster University, Hamilton, Ontario, Canada


Prof. Saskia Middeldorp, internist, professor of Vascular Medicine at the Academic Medical Center Amsterdam, The Netherlands

Dr. Hanna Pohjantähti-Maaroos, Heart Center, Kuopio University Hospital, Finland


Funding to produce this educational video series was provided by an unrestricted educational grant from Boehringer Ingelheim.

View the slides of this presentation Watch other videos from this series and read the Meeting Impression

Share this page with your colleagues and friends: